A downtrend has been apparent in Veru Inc. (VERU) lately. While the stock has lost 5.2% over the past week, it could witness ...

A downtrend has been apparent in Veru Inc. (VERU) lately with too much selling pressure. The stock has declined 9.2% over the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Veru has transitioned into a late clinical-stage biopharmaceutical company, concentrating on cardiometabolic and inflammatory diseases. CEO Mitchell Steiner highlighted enobosarm and sabizabulin ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Oatly Group AB (OTLY) 161.49% +5.22, Energy ...

$VERU insiders have traded $VERU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a ...

The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory disease, today announced ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation, pharmacokinetic ...